Back to top
more

Akebia Therapeutics (AKBA)

(Delayed Data from NSDQ)

$1.33 USD

1.33
2,551,324

-0.04 (-2.92%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $1.33 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for AKBA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Akebia Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 43 90 150 229 147
Receivables 39 40 51 67 39
Notes Receivable 0 0 0 0 0
Inventories 16 22 38 61 116
Other Current Assets 20 33 33 15 7
Total Current Assets 118 185 272 371 310
Net Property & Equipment 4 5 7 9 10
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 95 131 163 199 346
Deposits & Other Assets 12 5 50 38 76
Total Assets 242 356 526 644 771
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 15 18 34 41 39
Current Portion Long-Term Debt 18 32 98 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 68 76 104 131 129
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 4 21 15 40
Total Current Liabilities 100 130 256 187 208
Mortgages 0 0 0 0 0
Deferred Taxes/Income 43 43 21 25 33
Convertible Debt 0 0 0 0 0
Long-Term Debt 17 34 0 96 76
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 103 115 137 63 32
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 272 351 449 397 376
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,578 1,562 1,537 1,425 1,189
Retained Earnings -1,609 -1,557 -1,460 -1,178 -794
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -31 5 76 248 395
Total Liabilities & Shareholder's Equity 242 356 526 644 771
Total Common Equity -31 5 76 248 395
Shares Outstanding 188.30 183.90 174.90 144.50 118.90
Book Value Per Share -0.16 0.03 0.44 1.71 3.32

Fiscal Year End for Akebia Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 43 47 54 57
Receivables NA 39 23 20 18
Notes Receivable NA 0 0 0 0
Inventories NA 16 18 21 21
Other Current Assets NA 20 22 24 25
Total Current Assets NA 118 110 118 121
Net Property & Equipment NA 4 4 4 5
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 95 104 113 118
Deposits & Other Assets NA 12 4 3 5
Total Assets NA 242 235 254 277
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 15 9 12 13
Current Portion Long-Term Debt NA 18 8 24 24
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 68 63 56 46
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 100 80 92 83
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 43 43 43 43
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 17 35 18 26
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 107 115 111
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 272 274 281 291
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 1,578 1,570 1,568 1,565
Retained Earnings NA -1,609 -1,610 -1,595 -1,579
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA -31 -39 -27 -14
Total Liabilities & Shareholder's Equity NA 242 235 254 277
Total Common Equity 0 -31 -39 -27 -14
Shares Outstanding 209.30 188.30 188.30 185.90 185.90
Book Value Per Share 0.00 -0.16 -0.21 -0.14 -0.08